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Abstract
Purpose To compare HRQoL differences with CHD in
generic indexes and a proxy CVD-speciﬁc score in a
nationally representative sample of U.S. adults.
Methods The National Health Measurement Study, a
cross-sectional random-digit-dialed telephone survey of
adults aged 35–89, administered the EQ-5D, QWB-SA,
HUI2, HUI3, SF-36v2
TM (yielding PCS, MCS, and SF-
6D), and HALex. Analyses compared 3,350 without CHD
(group 1), 265 with CHD not taking chest pain medication
(group 2), and 218 with CHD currently taking chest pain
medication (group 3), with and without adjustment for
demographic variables and comorbidities. Data on 154
patients from heart failure clinics were used to construct a
proxy score utilizing generic items probing CVD
symptoms.
Results Mean scores differed between CHD groups for all
indexes with and without adjustment (P\0.0001 for all
except MCS P = 0.018). Unadjusted group 3 versus 1
differences were about three times larger than for group 2
versus 1. Standardized differences for the proxy score were
similar to those for generic indexes, and were about 1.0 for
all except MCS for group 3 versus 1.
Conclusions Generic indexes capture differences in
HRQoL in population-based studies of CHD similarly to a
score constructed from questions probing CVD-speciﬁc
symptoms.
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Cardiovascular disease (CVD) affects one-third of all
adults or nearly 81 million individuals in the United States
[1]. Coronary heart disease (CHD) is a substantial con-
tributor to both morbidity and mortality from CVD. CHD
leading to acute myocardial infarction (MI) remains one of
the most common causes of hospitalization, disability, and
death in the United States [1].
CHD or an MI has physical, emotional, and social
consequences. As improvements in survival of ischemic
events continue, researchers and clinicians acknowledge
that subjective assessment of HRQoL is necessary as a
complementary criterion for assessing prospective beneﬁts
of medical interventions [2–4]. Comparison of the impact
of CHD with that of other conditions on the population
level is clearly valuable for making public policy decisions
incorporating cost-effectiveness [5, 6].
Population studies typically use generic HRQoL indexes
[7]. It is not well known whether different generic indexes
of HRQoL give consistent estimates of the impact of CHD.
Some generic indexes such as the EuroQol EQ-5D
(EQ-5D) and the Medical Outcomes Study Short Form-36
(SF-36v2
TM) have been found to be valid measures in
patients with CHD [2–4, 8–10]. The EQ-5D, SF-6D, Health
Utilities Index Mark 2 (HUI2) and Health Utilities Index
Mark 3 (HUI3) have all been shown to be responsive to
other chronic diseases in populations, such as rheumatoid
arthritis [11, 12], type 2 diabetes [13], stroke [14], and
intermittent claudication [15].
Ontheotherhand,severalinstrumentshavebeendesigned
to speciﬁcally capture HRQoL with CHD or other cardio-
vascularconditions,andtendtobeusedinclinicalpopulations
[16–18] and in clinical practice [8, 10]. Comparing the per-
formanceofgenericindexestoadisease-speciﬁcinstrumentis
of interest to physician researchers who may wish to incor-
porate the use of generic instruments to monitor HRQoL.
There is some overlap in item content of CVD-speciﬁc
instruments and generic indexes allowing investigators to
potentiallyextractsubsets ofdisease-speciﬁcquestions touse
as proxy disease-speciﬁc HRQoL indicators.
The objective of this study was to assess six widely used
generic HRQoL indexes (the QWB-SA, SF-6D, EQ-5D,
HUI2, HUI3, and HALex) as well as the physical (PCS) and
mental health (MCS) subscales of the SF-36v2
TM in a pop-
ulation-basedsampleintermsoftheestimateddifferencesin
HRQoLbetweenindividualswithandwithoutCHDandwith
varying CHD severity. We compare effect sizesto those of a
proxy heart disease-speciﬁc index constructed from only
CHD-relevant questions within the QWB-SA. A parallel
sample of patients fromthree heartfailureclinicsallowedus
to derive an equation to combine these questions to predict
the CHD-relevant content of the Minnesota Living with
Heart Failure Questionnaire
 (MLHFQ) [16]. Comparison
with a proxy score simulating a CVD-speciﬁc instrument
provides a benchmarkwithwhich tocompare the abilitiesof
generic indexes. This comparison is valuable as clinicians
will increasingly be graded on performance as judged by
generic instruments [2].
Methods
Data collection
The National Health Measurement Study
The NHMS was a random-digit-dialed telephone interview
of a sample of non-institutionalized U.S. adults, ages
35–89 years, living in the contiguous United States in
2005–2006 [19]. Five generic HRQoL instruments were
administered in random order during the telephone inter-
view: SF-36v2
TM [20], the Health Utilities Index (HUI)
[21, 22], EQ-5D [23], the Self-Administered Quality of
Well-Being Scale (QWB-SA) [24], and the Health and
Activities Limitations Index (HALex) [25].
Sampling was in three stages: sampling telephone
numbers within telephone exchange strata, sampling an
age-stratum within households, and sampling a single
respondent from a selected age-stratum. Interviews were
conducted in English by trained interviewers at the Uni-
versity of Wisconsin Survey Center using commercial
computer-assisted telephone interview (CATI) software.
All subjects provided verbal informed consent. The survey
was approved by the Institutional Review Board at the
University of Wisconsin (protocol #H-2004-0083).
A total of 3,844 participants completed the interview,
representing an estimated response rate of 46%. For each
participant, a sampling weight was computed based on the
sampling design. Post-stratiﬁcation was used to further
adjusttheweightsfordifferentialresponseratesbyage,race,
and sex. Fryback et al. [19] provide further details about the
sampling techniques and weighting used for the NHMS.
Clinical Outcomes and Measurement of Health Study
A parallel study to the NHMS, the Clinical Outcomes and
Measurement of Health Study (COMHS) was conducted at
clinics for heart failure (HF) at the University of Wisconsin,
University of California, San Diego and University of Cali-
fornia, Los Angeles. Chronic heart failure cases newly
referred to the clinics were eligible if the left ventricular
ejection fraction was less than 50% for at least 3 months, as
measured by echocardiography, radiographic ventriculog-
raphy, or radionucleotide ventriculography. Furthermore, to
be enrolled in the study, patients had to be at least 35-years
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and understand verbal instructions in English, and have
sufﬁcientvisionandabilityinreadingandwritingEnglishto
complete the questionnaires. Data collected included the
generic HRQoL instruments administered in the NHMS
sample as well as the disease-speciﬁc MLHFQ. The instru-
ments were distributed to participants in paper form in a
packetassembledwiththegenericHRQoLquestionnairesin
randomized order, followed by the MLHFQ. Analyses
include baseline data from 154 participants who completed
thepacketofquestionnairesattheﬁrstclinicvisit.Thestudy
was approved by the Institutional Review Boards at the
University of Wisconsin (protocol #M-2005-1171) and the
University of California.
Generic HRQoL measures
Scoring according to the guidelines speciﬁc to each instru-
ment yielded the preference-scored indexes SF-6D (from
SF-36v2
TM [26]), HUI2 and HUI3 (from the HUI), EQ-5D,
QWB-SA,andHALex[21–25].Inaddition,thephysicaland
mental component scores (SF-36v2
TM PCS and SF-36v2
TM
MCS, respectively) were computed from the SF-36v2
TM
[20]. For the preference-based indexes, HRQoL is measured
by a single score anchored at dead (0.0) and full health (1.0)
[27]. The EQ-5D, HUI2, and HUI3 allow for scores ‘‘worse
than dead’’ with possible scores ranging from -0.11 to 1.0
forEQ-5D,-0.03to1.0forHUI2,and-0.36to1.0forHUI3
[23, 28]. The QWB-SA scores, excluding dead (0.0), can
rangefrom0.09to1.0[24],andSF-6Dfrom0.30to1.0[26].
The HALex score can range from 0.10 to 1.0 [25]. PCS and
MCSscoresfromtheSF-36v2
TMhavearangeof0–100,with
a mean score standardized at 50 and a standard deviation of
10 [20]. Fryback et al. [19] provided detailed descriptions of
all instruments and established population norms for these
generic indexes.
Deﬁnition of CHD subgroups
The NHMS telephone interview collected respondent-level
information frequently associated with HRQoL including
some details about eleven health conditions common in
U.S. adults. CHD was self-reported via the question ‘‘Have
you ever been told by a doctor or other health professional
that you had coronary heart disease or a heart attack, also
known as a myocardial infarction or MI?’’
Three CHD severity subgroups were deﬁned in the
NHMS population as follows: (1) no self-reported CHD
(n = 3,350), (2) self-reported CHD without current use of
chest pain medication (n = 265), and (3) self-reported
CHD with current use of chest pain medication (n = 218).
Current chest pain medication use was self-reported via the
question ‘‘Do you currently take medicine for chest pain?’’
Analyses exclude 11 who did not provide an answer to the
CHD question.
Development of proxy score
CHD is a common cause of HF [29] and the conditions share
symptoms. The item content of the MLHFQ emphasizes
activity, mobility limitations, and worry and is similar to that
of the Seattle Angina Questionnaire [17], but the latter con-
tains several items related to chest pain. Conversely, two
MLHFQ itemswereconsiderednot to apply toCHD (items 1
and 14, see Table 1). Several generic indexes also contain
items that resemble those in the MLHFQ (as displayed in
Table 1). Table 1 shows the polychoric correlation in the
COMHS sample between each ordinal MLHFQ item and its
genericmatches.Forthisandsubsequentpurposes,QWB-SA
items,whichaskedwhetherapersonhadsymptomsduringthe
past 3 days were dichotomized into whether a person had the
symptom at all (1) or not (0).
The QWB-SA had the largest number (11) of items
matchingtheMLHFQ,allofwhichhadpolychoriccorrelation
of[0.40 with the corresponding MLHFQ item. The MLHFQ
total score was recomputed in the COMHS sample, without
thetwoitemsdeemedapplicableonlytoHF,asthesumofthe
remainingitemsrescaledtotherangeoftheoriginalMLHFQ.
The CVD-speciﬁc proxy instrument was developed by linear
regressionofthismodiﬁedMLHFQtotalscoreonthematched
generic items from the QWB-SA. The resulting regression
coefﬁcients were used to create a scoring algorithm for the
proxy score, shown in the following equation, where the
predictorsareindividualitemvaluesfromtheQWB-SAitems
listedinTable 1.TheequationliststheQWB-SAitemsinthe
same order as they appear in Table 1, where the complete
wording of each item can be found.
Proxy score ¼ 25:7 þ 9:1   bed þ 9   walking
þ 3:9   work þ 7   sleep þ 1:7   social
þ 3:1   sex þ 2:5   diet þ 7:5   breathing
þ 17:7   nocontrol þ 0:54   worry
  0:6   confuse
The negative sign of the statistically non-signiﬁcant
coefﬁcient of the QWB item measuring confusion is due to
it having a negative polychoric correlation (-0.18) with
reporting side effects from treatments (item 16) on the
MLHFQ. The proxy score correlated with the modiﬁed
MLHFQ at r = 0.82.
Statistical analyses
All analyses were performed using SAS version 9.0 soft-
ware (The SAS Institute, Cary, NC). To produce nationally
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123Table 1 Individual items selected for analysis from generic HRQoL instruments
Minnesota Living with Heart Failure Questionnaire
items
Corresponding survey item from NHMS HRQoL instruments Polychoric
a
correlation
Did your heart failure prevent you from living as you
wanted during the past month by:
Questions were chosen from SF-36, QWB-SA-SA, and EQ-5D HRQoL
measurement instruments
1. Causing swelling in your ankles or legs? N/A to CHD
2. Making you sit or lie down to rest during the day? QWB-SA bed: Over the past 3 days did you spend all or most of the day
in a bed, chair, or couch because of physical reasons?
0.56
3. Making your walking about or climbing stairs
difﬁcult?
Does your health limit you in these activities? If so, how much?
SF 6: Climbing several ﬂights of stairs? 0.65
QWB-SA walking: Over the past 3 days did you avoid walking, have
trouble walking, or walk more slowly than other people your age?
0.73
4. Making your working around the house or yard
difﬁcult?
QWB-SA limit work: Over the past 3 days because of any physical or
emotional health reasons, on which days did you avoid, need help
with, or were limited in doing some of your usual activities, such as
work, school, or housekeeping?
0.53
5. Making your going places away from home
difﬁcult?
Does your health limit you in these activities? If so, how much?
SF 10: Walking several hundred yards? 0.60
EQ5D1: Would you say you have no problems in walking about, some
problems in walking about, or are you conﬁned to bed?
0.61
6. Making your sleeping well at night difﬁcult? QWB-SA sleep: On any of the past 3 days did you have trouble falling
asleep or staying asleep?
0.63
7. Making your relating to or doing things with your
friends or family difﬁcult?
SF 32: During the past 4 weeks, how much of the time has your physical
health or emotional problems interfered with your social activities,
like visiting friends, relatives, etc.?
0.67
8. Making your working to earn a living difﬁcult? SF 16: How much of the time did you have difﬁculty performing your
work or other activities (for example it took extra effort)?
0.58
9. Making your recreational pastimes, sports, or
hobbies difﬁcult?
EQ5D3: Would you say you have no problems performing your usual
activities, some problems performing your usual activities, or are you
unable to perform your usual activities?
0.46
QWB-SA limit social: Over the past 3 days because of physical or
emotional health reasons, on which days did you avoid or feel limited
in doing some of your usual activities, such as visiting family/friends,
hobbies, shopping, recreational, or religious activities?
0.55
10. Making your sexual activities difﬁcult? QWB-SA sex: On any of the past 3 days did you have any decrease of
sexual interest or performance?
0.73
11. Making you eat less of the foods you like? QWB-SA diet: On any of the past 3 days did you have to stay on a
medically prescribed diet for health reasons?
0.43
12. Making you short of breath? QWB-SA breathing: On any of the past 3 days did you have shortness of
breath or difﬁculty breathing?
0.78
13. Making you tired, fatigued, or low on energy? SF 29: How much of the time during the past 4 weeks did you feel worn
out?
0.72
SF 31: How much of the time during the past 4 weeks did you feel tired? 0.77
14. Making you stay in a hospital? N/A to CHD
15. Costing you money for medical care? N/A
16. Giving you side effects from treatments? N/A
17. Making you feel you are a burden to your family or
friends?
SF 25: How much of the time during the past 4 weeks have you felt so
down in the dumps that nothing could cheer you up?
0.57
18. Making you feel a loss of self-control in your life? QWB-SA no control: On any of the past 3 days did you have feelings
that you had little or no control over events in your life?
0.71
19. Making you worry? QWB-SA worry: On any of the past 3 days did you have excessive worry
or anxiety?
0.68
20. Making it difﬁcult for you to concentrate or
remember things?
QWB-SA confuse: On any of the past 3 days did you have confusion,
difﬁculty understanding the written or spoken word, or signiﬁcant
memory loss?
0.82
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123representative estimates of index means and differences,
further analyses incorporated trimmed post-stratiﬁcation
sampling weights and accounted for telephone exchange
strata.
Weighted means and standard deviations of the generic
instruments and proxy score within CHD subgroups were
computed. Higher scores indicate better HRQoL on the
generic measures. As the CVD-speciﬁc proxy score was
developed to resemble the MLHFQ, scoring is reversed for
this index; so higher scores represent an increase in prob-
lematic symptoms and thus worse HRQoL. Both unadjusted
and adjusted differences in mean scores were estimated and
statistical signiﬁcance of group differences assessed by
F-tests implemented in SAS PROC SURVEYREG. Differ-
ences were ﬁrst adjusted in a joint model across groups for
age (as a continuous predictor),race (white, black, and other
categories) and sex, and then additionally for arthritis,
respiratory disease and diabetes (comorbidities that share
symptoms with CHD). Group differences adjusted for these
comorbidities were also obtained.
Standardized group differences were estimated from the
means adjusted for age, race, and sex, and the residual
standard deviation of the adjustment model. An effect size
of 1 corresponds to a one standard deviation difference in
magnitude. Guidelines for interpreting standardized dif-
ferences are well established, with 0.2–0.5 representing a
small effect size, 0.5–0.8 medium, and [0.8 large [30].
Weighted Pearson partial correlations, adjusted for age,
race, and sex between the proxy score and the scores for all
generic instruments were also obtained.
Results
The three CHD severity subgroups were described by
unweighted statistics (Table 2). Mean scores for the proxy
index and each of the generic indexes weighted to the U.S.
population are also reported (Table 3). Those without CHD
have the lowest proxy score, followed by those with only
CHD and those with CHD plus chest pain medication use.
This suggests that higher proxy scores reﬂect worse CVD-
related health. All generic score means for respondents
with CHD are lower than for those without CHD. Differ-
ences in unadjusted and adjusted mean scores between the
three CHD subgroups were calculated (Table 4) and were
signiﬁcant for all indexes (P = 0.018 for SF-36 MCS, all
others P\0.0001). The minimally important difference is
considered to be 0.03 for the EQ-5D, QWB-SA, HUI2, and
HUI3, 0.033 for the SF-6D, and 5 for the SF-36v2
TM MCS
and SF-36v2
TM PCS [31, 32]. Unadjusted and adjusted
mean score differences for these generic indexes between
all CHD severity subgroups exceeded clinically signiﬁcant
Table 1 continued
Minnesota Living with Heart Failure Questionnaire
items
Corresponding survey item from NHMS HRQoL instruments Polychoric
a
correlation
21. Making you feel depressed? SF 28: How much of the time during the past 4 weeks have you felt
downhearted and depressed?
0.80
a QWB items are highlighted in italics, and were dichotomized into ‘‘occurred during the last 3 days’’ versus ‘‘did not occur during the last 3
days’’
Table 2 Descriptive statistics for NHMS sample (unweighted)
No
CHD
CHD
only
CHD ?
meds
N 3,350 265 218
Mean age (SD) 58.9 (14.0) 69.9 (10.2) 68.9 (10.7)
Sex (%)
Male 41.2 57.0 49.1
Female 58.8 43.0 50.9
Race (%)
White 66.2 75.9 62.4
Black 28.8 20.4 30.7
Other 4.5 3.4 6.9
Health conditions (%)
Stroke 3.5 15.1 21.6
Diabetes 16.1 30.2 46.8
Arthritis 37.4 53.6 69.7
Sleep disorder 8.1 13.6 22.0
Chronic respiratory
disease
15.3 21.1 32.1
Thyroid disorder 11.7 14.7 17.4
Chronic back pain 16.6 25.3 43.6
Depression (%)
Clinical depression or
anxiety
14.0 14.7 22.5
Take depression/anxiety
medication
8.7 8.7 16.5
Smoking (%)
Ever smoked 50.8 66.8 67.0
Currently smoke
everyday
15.1 12.5 13.8
Cardiac treatment (%)
Bypass surgery – 28.3 33.0
Coronary angioplasty – 37.0 52.3
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123values, with the exception of the SF-36v2
TM MCS.
Differences between CHD subgroups 1 and 3 tended to be
2–3 times greater than the differences between CHD sub-
groups 1 and 2. Adjusted differences controlling for dia-
betes, arthritis, and chronic respiratory disease were
smaller than unadjusted differences, but remain statistically
and clinically signiﬁcant.
Three effect sizes were calculated for each instrument:
thosewithCHDwithoutchestpainmedicationscomparedto
thosewithoutCHD(subgroup2vs.1),thosewithCHDusing
chestpainmedicationscomparedtothosewithCHDwithout
chest pain medications (subgroup 3 vs. 2), and those with
CHD using chest pain medications compared to those
without CHD (subgroup 3 vs. 1). The effect sizes are shown
inTable 5.TheresultsshowtheHALex,theSF-36v2
TMPCS
and the proxy score to have the largest effect sizes in all
comparisons, and the SF-36v2
TM MCS to have the lowest.
However, while the HUI2 and HUI3 differentiate next best
between the CHD groups taking and not taking chest pain
medication, the QWB-SA has a larger effect size between
those with CHD without chest pain medication and those
without CHD. All measures except the SF-36v2
TM MCS
have strong effect sizes between those with CHD taking
chest pain medication and those without CHD.
Partial correlations demonstrated that all of the generic
indexes correlated highly with the CVD-speciﬁc proxy
score, in both the NHMS sample as a whole and in a
subgroup of only those with self-reported CHD (severity
subgroups 2 and 3 combined) (Table 6).
Discussion
This study is the ﬁrst to examine the abilities of six simul-
taneously administered generic instruments to detect
HRQoL differences related to CHD in a cross-sectional,
nationally representative sample of U.S. adults. The total
scores for all indexes demonstrated ability to differentiate
between individuals with and without CHD, and between
CHD severity subgroups deﬁned by self-reports of taking or
not taking medication for chest pain. The generic indexes
correlated highly with a proxy CVD-speciﬁc index. While
the QWB-SA and SF-36v2
TM appeared to have the greatest
overlap of questions with heart speciﬁc instruments, it is
worth noting these generic indexes did not display larger
effectsizesthantheotherindexes.Notably,theHUI2,HUI3,
and HALex have large effect sizes, and also correlate highly
withtheproxyindex.Itislikelythatmuchoftheequivalence
between measures is caused not only by items that are
explicitly similar, but also the fact that heart disease may
Table 3 Mean HRQoL scores and standard deviations weighted to
US population
Unadjusted No CHD CHD w/o meds CHD with meds
Mean SD Mean SD Mean SD
Proxy CVD score 32 11 37 13 45 16
EQ-5D 0.88 0.15 0.82 0.15 0.74 0.21
QWB-SA 0.66 0.14 0.58 0.14 0.52 0.14
HUI2 0.86 0.16 0.80 0.17 0.69 0.23
HUI3 0.82 0.23 0.75 0.25 0.56 0.35
SF-6D 0.80 0.13 0.75 0.13 0.67 0.15
SF-36 MCS 54 8.5 53 9.7 51 12.4
SF-36 PCS 50 9.0 44 10.6 35 11.8
HALex 0.82 0.19 0.68 0.23 0.50 0.24
Table 4 Unadjusted and adjusted differences in mean scores between
CHD groups
No CHD - CHD
w/o meds
(standard error)
No CHD - CHD
with meds
(standard error)
P value
c
Unadjusted
Proxy CVD score -4.6 (1.1) -12 (1.7) \.0001
EQ-5D 0.055 (0.013) 0.14 (0.022) \.0001
QWB-SA 0.095 (0.013) 0.15 (0.015) \.0001
HUI2 0.051 (0.017) 0.17 (0.024) \.0001
HUI3 0.068 (0.024) 0.26 (0.039) \.0001
SF-6D 0.048 (0.012) 0.13 (0.019) \.0001
SF-36 MCS 0.59 (0.94) 2.9 (1.2) 0.018
SF-36 PCS 6.2 (0.96) 15 (1.4) \.0001
HALex 0.13 (0.023) 0.32 (0.027) \.0001
Adjusted
a
Proxy CVD score -5.7 (1.1) -13 (1.7) \.0001
EQ-5D 0.047 (0.013) 0.12 (0.023) \.0001
QWB-SA 0.077 (0.012) 0.13 (0.016) \.0001
HUI2 0.050 (0.017) 0.16 (0.024) \.0001
HUI3 0.065 (0.024) 0.25 (0.040) \.0001
SF-6D 0.045 (0.012) 0.12 (0.020) \.0001
SF-36 MCS 2.0 (0.95) 3.9 (1.3) 0.0024
SF-36 PCS 4.2 (0.96) 13 (1.4) \.0001
HALex 0.11 (0.024) 0.29 (0.028) \.0001
Adjusted
b
Proxy CVD score -5.2 (1.2) -9.2 (1.6) \.0001
EQ-5D 0.038 (0.013) 0.084 (0.020) \.0001
QWB-SA 0.069 (0.013) 0.088 (0.014) \.0001
HUI2 0.038 (0.018) 0.12 (0.021) \.0001
HUI3 0.047 (0.025) 0.19 (0.035) \.0001
SF-6D 0.038 (0.012) 0.082 (0.017) \.0001
SF-36 MCS 1.8 (0.97) 2.6 (1.3) 0.038
SF-36 PCS 3.6 (0.90) 9.6 (1.2) \.0001
HALex 0.098 (0.025) 0.21 (0.027) \.0001
a Adjusted for age, sex, and race
bAdjusted for age, sex, race, arthritis, respiratory disease, and diabetes
c P value by F-test across groups
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123cause many general health problems. Based on these ﬁnd-
ings, it appears that administering CHD speciﬁc instruments
togeneralpopulationsampleswillbeoflimitedvalue.These
ﬁndings may also be of interest to clinicians, as there is
increasing interest in the administration of generic HRQoL
indexes to monitor patients in the ambulatory setting [2].
Items within generic measures may offer much of the
information captured by disease-targeted approaches.
Genericmeasuresmightbeadaptedtoofferbothgeneraland
disease-speciﬁc assessment.
There is relatively little difference between the generic
indexes in their sensitivity to CHD-related HRQoL. Effect
sizes were of similar magnitude to that of the proxy score
for the MLHFQ, even between severity subgroups 2 and 1.
Much CHD in this lower severity group could be asymp-
tomatic, and part of the effect on HRQoL may be through
the diagnostic label itself. Part of the HALex total score is
based on a self-reported health scale, while other indexes
ask respondents to report functioning not feelings. This
difference may be important for conditions that are serious
but not associated with many symptoms. HUI3 and HUI2
have higher effect sizes and absolute differences with the
CHD group taking chest pain medication, while QWB-SA
has a greater effect size with the CHD group not taking
chest pain medication. This ﬁnding is consistent with the
HUI3 having large score decrements with health states at
the lowest range of health, while the QWB-SA contains
more items sensitive at the higher end of health.
The analyses presented in this study have limitations.
One limitation is that the proxy CVD-speciﬁc index is not a
validated, disease-speciﬁc instrument such as the Seattle
Angina Questionnaire [17]. Although there is overlap in
item content, questions in our proxy score are not as spe-
ciﬁc with respect to physical functioning with CHD as
those in the Seattle Angina Questionnaire. Our score also
does not contain questions speciﬁc to chest pain, which
may have led to lower sensitivity to CHD.
Another limitation is that both CHD and current chest
pain medication use were self-reported in the NHMS
population, and the study design did not include veriﬁca-
tion of self-report with clinical records. The accuracy of
self-report for MI was investigated by Heckbert et al. [33]
in the Women’s Health Initiative Study, and good agree-
ment was reported between self-report and physician
review of medical records (kappa = 0.64). Speciﬁcity was
very high at 99%, while sensitivity was lower at 64%.
Based on this report, HRQoL differences in our study may
be somewhat attenuated, as some individuals may have
been diagnosed with CHD but did not report it and some
patients with symptomatic CHD have not been diagnosed.
Furthermore, some individuals may have reported chest
pain medication use if they have a prescription for nitro-
glycerin, regardless of how often or infrequently they need
to use it. Such circumstances would all lead to our effect
sizes being underestimated, lending further support to the
Table 5 Effect sizes between CHD severity groups
Index score Difference between
CHD only and no CHD
a
Difference between
CHD ? meds and CHD only
a
Difference between
CHD ? meds and no CHD
a
Proxy CVD score 0.51 0.62 1.13
EQ-5D 0.32 0.52 0.84
QWB-SA 0.52 0.36 0.88
HUI2 0.31 0.72 1.03
HUI3 0.28 0.81 1.09
SF-6D 0.36 0.58 0.94
SF-36 MCS 0.24 0.22 0.45
SF-36 PCS 0.49 0.97 1.46
HALex 0.57 0.93 1.50
For effect size calculation, differences in mean HRQoL scores were standardized to population standard deviation among those without CHD
from Table 4. Root mean squared error for model with index score as outcome and CHD group and adjustment variables (age, sex, gender) as
predictors was used for standardization
a Reference group
Table 6 Correlations between proxy score and generic indexes,
partial on age, sex, and race
Index score All NHMS participants
proxy score
NHMS all CHD
proxy score
EQ-5D -0.63 -0.65
QWB-SA -0.67 -0.76
HUI2 -0.69 -0.69
HUI3 -0.68 -0.69
SF-6D -0.62 -0.66
SF-36 MCS -0.51 -0.56
SF-36 PCS -0.57 -0.54
HALex -0.60 -0.55
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subgroups.
As with any data obtained via survey, differential par-
ticipation and response rates between groups are a limita-
tion. Telephone surveys are particularly limited, as calls are
often screened and an increasing number of households
rely only on cellular phones, which are not included in
random-digit-dialed household sampling. However, it has
been reported that in the time the NHMS survey was
completed this seems to have had little effect on population
health estimates [34]. Furthermore, as several different
HRQoL indexes were administered, the length of the
interview and the time required to complete it may have led
to the selection of participants with higher education and/or
better health. This would likely have resulted in underes-
timation of the differences in indexes between CHD
subgroups.
Despite these limitations, our results contribute an
important ﬁnding to the ﬁeld of cardiovascular research.
Generic indexes can capture differences in HRQoL
between populations with and without CHD. These dif-
ferences are similar to those detected by questions specif-
ically targeted at cardiovascular disease, and appear to also
be valid as an indication of disease severity within a CHD
population.
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